References
- Nutting CM, Jenkins CD, Norton AJ, . Primary orbital lymphoma. Hematol J 2002;3:14–16.
- Bischof M, Karagiozidis M, Krempien R, . Radiotherapy for orbital lymphoma: outcome and late effects. Strahlenther Onkol 2007;183:17–22.
- Fung CY, Tarbell NJ, Lucarelli MJ, . Ocular adnexal lymphoma: clinical behavior of distinct World Health Organization classification subtypes. Int J Radiat Oncol Biol Phys 2003;57:1382–1391.
- Goda JS, Le LW, Lapperriere NJ, . Localized orbital mucosa-associated lymphoma tissue lymphoma managed with primary radiation therapy: efficacy and toxicity. Int J Radiat Oncol Biol Phys 2011;81:e659–e666.
- Jeganathan VS, Wirth A, MacManus MP.Ocular risks from orbital and periorbital radiation therapy: a critical review. Int J Radiat Oncol Biol Phys 2011;79:650–659.
- Kaushik M, Pulido JS, Schild SE, . Risk of radiation retinopathy in patients with orbital and ocular lymphoma. Int J Radiat Oncol Biol Phys 2012 May 15. [Epub ahead of print]
- Stefanovic A, Lossos IS.Extranodal marginal zone lymphoma of the ocular adnexa. Blood 2009;114:501–510.
- Tran K, Campbell BA, Fua T, . Efficacy of low dose radiotherapy for primary orbital marginal zone lymphoma. Leuk Lymphoma 2013; 54:491–496.
- Tsang RW, Gospodarowicz MK.Radiation therapy for localized low-grade non-Hodgkin's lymphomas. Hematol Oncol 2005;23:10–17.
- Esmaeli B, McLaughlin P, Pro B, . Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma. Ann Oncol 2009;20:709–714.